EAGLE PHARMACEUTICALS, INC. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q2 2020 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Eagle Pharmaceuticals, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q2 2020 to Q2 2023.
  • Eagle Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2023 was $5.16M.
  • Eagle Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending June 30, 2023 was $8.56M, a 67.1% decline year-over-year.
  • Eagle Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $34.6M.
  • Eagle Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$8.72M, a 173% decline from 2020.
  • Eagle Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was $12M, a 16.2% decline from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $8.56M $5.16M +$12.8M Apr 1, 2023 Jun 30, 2023 10-Q/A 2023-08-09
Q1 2023 -$4.2M $5.75M -$38.8M -87.1% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $34.6M -$2.32M +$3.08M +57% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-23
Q3 2022 $31.5M -$35K +$5.57M +99.4% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-09
Q2 2022 $26M -$7.59M -$10.3M -380% Apr 1, 2022 Jun 30, 2022 10-Q/A 2023-08-09
Q1 2022 $36.3M $44.6M +$45M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$8.72M -$5.41M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 -$5.6M -$12.7M -179% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $2.71M +$2.96M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$421K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q3 2020 $7.06M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$256K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.